|
 The company said on Tuesday the experimental drug, HTX-011, was
better than a placebo in reducing pain in patients who had undergone
bunionectomy, a surgery to remove an enlarged portion of the feet.
The drug reduced pain intensity by 69 percent in 24 hours and by 40
percent in 72 hours, the company said.
HTX-011, a combination of local anesthetic bupivacaine and
anti-inflammatory meloxicam, was well-tolerated in the study.
The company has been focusing on the experimental pain drug after
having applied for U.S. marketing approval for its drug Sustol to
treat chemotherapy-induced vomiting and nausea.
AcelRx Pharmaceuticals Inc, Innocoll AG, Insys Therapeutics Inc and
Ocular Therapeutix Inc are among companies developing rival
post-operative painkillers.
Up to Tuesday's close of $33.56, the company's shares had more than
tripled this year. The shares gained 60 percent in late-May,
following positive late-stage study data on Sustol.
[to top of second column] |
(Reporting by Vidya L Nathan in Bengaluru; Editing by Sriraj
Kalluvila)
[© 2015 Thomson Reuters. All rights
reserved.] Copyright 2015 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
